Double-Punch therapy trial targets most aggressive blood cancer
NCT ID NCT05632380
Summary
This study is testing a two-part treatment for patients with very high-risk multiple myeloma, a blood cancer, that hasn't responded well to standard first-line therapy. Doctors will collect a patient's own stem cells and immune cells, give a stem cell transplant, and then infuse specially engineered CAR-T cells designed to attack the cancer. The goal is to see if this combination is safe and can better control the disease in these difficult-to-treat cases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, 300020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.